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IThasforlongbeenanacceptedprinciple that the earlierthe diagnosisof malig-
nant disease is made the more likely it is that the growth, if in a region of the
body accessible to the surgeon, will be in a stage which admits of radical re-
section and the higher will be the survival rate. However, Balfour (1937) recorded
that the 5-year survival rate for 2112 patients after resection of the stomach
for carcinoma was 25 per cent for those patients with histories of symptoms for
less than 6 months and 35 per cent for those with histories ofsymptoms for more
than one year. Walters, Gray and Priestley (1942) in a later study recorded that
24*6 per cent of patients whose symptoms were of less than one year's duration
survived 5 years after resection of the stomach for carcinoma, whereas 32-6
per cent of patients the duration of whose symptoms was more than one year
survived 5 years. Swynnerton and Truelove (1952) reported on 375 patients with
carcinoma of the stomach, 114 of whom were treated by resection; they found
that the 3-year survival rate of 26 whose symptoms were of less than 6 months'
duration was 7-7 per cent, of 22 whose symptoms were of 6 months' to 2 years'
duration was 36-4 per cent, while for 24 whose symptoms were of over 2 years'
duration the survival rate was 54*2 per cent. These differences in survival rate
were found to be statistically significant (P < 0.01). After an analysis of the
age distribution of the patients, the site of the lesion and the possibility that the
patients with long histories were examples of " ulcer-cancer ", the authors con-
cluded that these factors " do not serve to explain the good prognosis of patients
with a long history in the resected group, and we believe that this association
is due to the occurrence ofslow-growing carcinomata ". The authors investigated
the association between the length of history and the grade of malignancy as
judged by Broders' classification, and give a table which shows that 39 of the
114 patients had growths which were classified as Broders' Groups I and II,
while 75 had growths classified as Broders' Groups III and IV; in each case the
proportion of patients who gave histories of symptoms for more than 2 years
was 23 per cent.
Eggers, de Cholnoky and Jessop (1941) reported that while the 5-year sur-
vivals of 235 patients who had undergone radical.mastectomy for cancer of the
breast fell steadily from 76 per cent to 20 per cent with delay in treatment up to
2 years, the survival rates rose to 25 per cent of 20 patients in whom the delay
was over 2 years, and to 40*9 per cent of22 patients in whose cases-there had been
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tomies for cancer of the breast, found that 24-8 per cent of the 938 5-year sur-
vivors were treated more than one year after recognition of the tumour; he
considered that the majority of these cases were the indolent, slowly-growing
types of breast carcinoma, which metastasized late or occurred in hosts whose
desmoplastic reaction to the tumour was intense. Bloom (1950a) in an analysis
of 470 cases of cancer of the breast treated by surgery alone or with ancillary
radiotherapy found, after classifying them into 3 groups according to histological
criteria of degree of malignancy, that 79 per cent of 141 cases graded as of low
malignancy survived 5 years, 42 per cent of 191 graded as of moderate malignancy
and 25 per cent of 138 graded as of high malignancy; when the histological
grading was subdivided according to the presence or absence of invasion of the
axillary lymph nodes, he found that with lymph nodes not invaded the 5-year
survival rates for GradesI, II and III were 94, 61 and 53 per cent respectively,
while for patients in whom the lymph nodes were demonstrated histologically
to be invaded the survival rates for the three grades were 65, 30 and 16 per cent
respectively. Investigating the relationship between duration of symptoms and
prognosis according to the grade of malignancy in the same series of cases, Bloom
(1950b) found that of the patients with Grade I tumours 92 per cent of those
attending hospital within 6 weeks ofthe first symptom survived 5 years, compared
with 72 per cent of those who had waited 6 to 12 months and 78 per cent of those
who had delayed more than 12 months. Those with Grade II tumours showed a survival rate of 41 to 47 per cent for periods of delay of up to 12 months, rising
sharply to 50 per cent for those who had delayed more than 12 months, while
for Grade III cases the survival rates fell from 29 per cent for those with only
6 weeks' delay to 21 per cent for those with more than 12 months' delay. It
was found that 56 per cent of the patients with Grade I tumours came to hospital
within 6 months and 23 per cent delayed more than 12 months, whereas for
Grade III tumours the figures were 69 per cent and 10 per cent, showing that the
most malignant neoplasms were associated with the shortest history and the
patients with these tumours consulted their doctors earlier.
Park and Lees (1951) discussed in general terms the influence on survival rates
of patients with cancer of the breast of variations in growth rate of individual
tumours, infiltrating and metastasising potential, date of onset of symptoms,
available time margin between the date when a tumour firstbecame diagnosable
and when it gave rise to regional and later incurable general metastases. They
concluded that there was no direct evidence that delay in treatment diminished
the cure rate, that the difference in 5-year survival rate between treated and
untreated patients with cancer of the breast was about 20 per cent, that the
difference between those operated on at the time of discovery of the tumour
and those in whom there was delay of 3 years was 7 5 per cent, and that apparent
curability can be explained in terms of variability of growth rate. Proof of
curability will be given by a positive relation between decrease in survival rate
and increased delay in treatment for cancers of the same degree of malignancy,
fromwhich it follows that the more rapidly growing the tumour the less the
margin of time available for successful treatment and the greater the diminution
of survival rate for a given time-delay. In an editorial comment the British
Medical Journal (1952) remarks that Park and Lees
"have made a strong case
for attributing much of the benefit customarily allowed to surgery to the selection
of patients with a naturally good prognosis."
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In the analysis of 14,182 primary cases of cancer collected from London
Hospitals by the Clinical Cancer Research Committee of the British Empire
Cancer Campaign, Harnett (1952) gives for each region of the body the interval
from first symptom to first consulting a doctor, which was over 6 months for
208 per cent of all patients, and the duration of symptoms at the time of com-
mencing treatment, with comparison ofthe survival rates of those in whose cases
it was over or under 6 months respectively. As all types of treatment, surgery,
radiotherapy and combined treatment, whether radical or palliative, were in-
cluded, it is not surprising that few significant differences in survival rate were
detected, thoughin mostregions it appeared that thepatients treated earlyshowed
little better survival rates than those who came late.
In the present communication tabulations are presented from the same series
of cases of the results of treatment of patients in Stages I, II or III, who were
treated by radical surgery alone or combined with radiotherapy, arranged accord-
ing to duration of symptoms at the time of commencing treatment. By the
elimination of all patients who were in Stage IV, and of those in whose cases
only operations of a palliative nature were performed, the series is restricted to
those in whom there was a reasonable expectation of 5-year cure. Patients
treated by radiotherapy alone have been excluded, because it is difficult to
separate those in whose cases the treatment was intended to be curative from
those in which it was palliative only, though some of the latter survived 5 years.
The cases are grouped by site of the disease and by duration of symptoms at the
time of commencing treatment into (a), those in which the interval from first
symptom to commencement of treatment was less than 6 months, (b), those in
which it was between 6 and 12 months, (c), those in which it was more than 12
months, (d), those in which it was unknown. The 5-year survival rates for each
of these groups is expressed as a percentage of the total in the group, and the
standard errors of the differences have been calculated to test for statistical
significance. In the more important sites the survivals are shown by stages:
I. Confined to organ or tissue of origin, lymph nodes not involved.
II. Adjacent tissues invaded, but lymph nodes not involved clinically.
III. Lymph nodes involved clinically, with or without invasion of
adjacent tissues.
In certain regions, stomach, kidney, testis, penis, breast and sarcoma of soft
tissue, it is customary to classify cases with involvement of the regional lymph
nodes as Stage II and those with invasion of adjacent tissues as Stage III;
allowance has been made for this difference when necessary.
It was found that in some regions the highest percentage of 5-year survivals
was among those patients who came for treatment in the first 6 months, in others
the highest percentage was among those who came in the second 6 months, and
in others it was among those who came after symptoms had been noticed for
more than one year. Accordingly the cases have been arranged in three groups
(Tables I-VII).
For the whole group of 1097 cases of known duration the difference between
those treated in the first 6 months and those treated later is the difference between
survival rates of51e1 per cent and of42-0per cent, which is 9-1 per cent. Detailed
figures of survival by stages are given in Table II for squamous carcinoma of
the skin, corpus uteri, female breast and kidney; for the other regions in the
group all stages are combined.
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A. The highest percentage of 5-year survivals was among the patients who were
treated within the first 6 months.
TABLE I.
Site.
Skin, squamous car-
cinoma
Corpus uteri
Penis
Cervix uteri
Female breast
Kidney
Bladder, papillary car-
cinoma
Pharynx
Totals
Per cent survived
Difference
0-6 months.
No. Survd.
55
62
17
43
346
23
38
39
10
24
171
11
6-12 months. Over 12 months.
No. Survd. No. Survd.
22
46
7
-17
84
10
5
24
4
7
35
1
56 20 . 21 7
14 2 . 4 -
616 315 . 211 83
0- _v_- t
y
51.1 39 3
118
42
51
6
9
111
12
23
28
1
4
51
4
33 7
6 1
270 119
44 1
4 8
TABLE II.
Skin--squamous carcinoma.
Stage I. Stage II. Stage III.
Duration. , -I r- > 5
No. Survd. No. Survd. No. Survd.
0-3 months . 25 21 . 4 2 . 4 2 .
3-6 ,, . 19 12 . 2 1 . 1 -
6-12 ,, . 18 4 . 2 1 . 2 -
Over 12 ,, . 29 20 . 7
Totals.
f, Per cent.
No. Survd.
33 251 ±- 22 133
. 69 1+6s2}
22 5 . 22 7±8.9
1 . 6 2 . 42 23 . 54 8±7 7
Not known . 9 3 . 5 2 . 5 - . 19 5
Both the above differences in survival rate are statistically significant.
For cases of known duration X2=13 69, n=2, P <.01> *001.
Corpus uteri.
Duration.
0-3 months
3-6 ,,
6-12 ,,
Stage I.
No. Survd.
26 18 .
24 17 .
35 19 .
Over 12 ,, . 37 19 -
Stage II. Stage III. Totals.
- r-- -,- "i1 - 5 Per cent.
No. Survd. No. Survd. No. Survd.
3 1 . 2 1 . 31 20'96l 2 1 . 5 1 . 31 19f .62@9+6*
8 4 . 3 1 . 46 24 .52.2+7.3
13 8 . 1 1 . 51 28 . 54-9+7-0
Notknown . 5 2 . 1 - . - . 6
The differences in survival rate are not statistically significant.
For cases of known duration x2=1X41, n=2, P < *50> *30.
2
Female breast.
Stage I. Stage II.
Duration. , A r5 1#
No. Survd. No. Survd.
0-3 months . 79 44 . 87 44
3-6 ,, . 30 22 . 45 16 .
6-12 ,, . 26 15 . 25 12 .
Over 12,, . 30 19 . 19 7
Stage III. Totals. - 1 A 1 Per cent.
No. Survd. No. Survd.
53 21 . 219 109 -4±2-7 52 24 .127 62 5. 491 4
33 8 . 84 35 . 41-7+54 .4
62 25 . 111 51 . 45 9±4 7 ±7-2
Not known . 8 3 . 6 2 . 3 1 17
The differences in survival rate are not statistically significant.
For cases of known duration X2=1X77, n=2, P < 50> 30.
6
22
Not known.
No. Survd.
19
6
1
2
17
1
5
2
2
6
1 _
1 _
48 15
2- J
31-2
Differ-
ence.
46 4
±10.9
32-1
±9 9
Differ-
ence.
10 7
, 11.9
Differ-
ence.
7.7
i ()DELAY IN TREATMENT OF CANCER AND SURVIVAL RATE
Kidney.
Duration.
0-3 months
3-6 ,
6-12 ,,
Over 12 ,
TABLE II-continued.
Stage I. Stage II. Stage III. Totals.
,~--A-----~ , , , , Per cent.
No. Survd. No. Survd. No. Survd. No. Survd. ence.
7 3 . 1 1. 5 1.13 5} 781~ 7
5 3 .- - 5 3 10 6 }473 +1
8 1 . - _ . 2 - . 10 1 .100+ 9 5X23± 3
10 3 . 1 - . 1 1 . 12 4 .33*3±13.6 f16 6
Not known . 1 - . - - . - - . 1
The difference in survival rate between those of duration 0-6 months and those of duration
6-12 months, 37 8+14 1, is statistically significant.
For cases of known duration x2=-440, n=2, P < *20> * 10.
Peni8.
Duration.
0-3 months
3-6 ,,
6-12 ,
Over 12 ,
Not known
All stages.
No. Survd.
12 8j
5 2
7 4
6 1
1 -
Per cent.
. 58-8+11-9
. 57 1+18-7
. 16 6±15*2
Difference.
1*7±22 1
40-5±24' 1
The differences in survival rate are not statistically significant.
For cases of known duration x2=3* 32, n=2, P < 20> * 10.
Cervix uteri.
Duration.
0-6 months
6-12 ,,
Over 12 ,
Not known
All stages.
r -A Per cent.
No. Survd.
43 24 . 55 8i 7 6
17 7 . 41b2±11-9
9 4 . 44-4+16-5
2 2
Difference.
14 6+14 1
3-2±20-4
The differences in survival rate are not statistically significant.
For cases of known duration x2=1X20, n=2, P < *70> *50.
Bladder-papillary carcinoma.
Duration.
0-6 months
6-12
Over 12 ,
Not known
All stages.
No. Survd.
56 20
21 7
33 7
1 -
Per cent.
. 35-7± 6-4
. 33 3±10 3
. 21-2± 7 1
Difference.
2-4±12 1
12 1±12 5
The differences in survival rate are not statistically significant.
For cases of known duration x2=2 12, n=2, P < 50> 30.
Pharynx .
Duration.
0-6 months
6-12 ,,
Over 12 ,
Not known
All stages.
,r A -1, Per cent.
No. Survd.
14 2 . 14-3±9-3
4 - . 10.0±9.5 6 1
1 -
Difference.
4-3±13-3
The differences in survival rate are not statistically significant.
For cases of known duration x2= - 102, n=1, P < 80> 70.
All cases of cancer of the female breast in Stages I, II and III are included
in this table, whether treated by radical mastectomy alone or combined with
radiotherapy. The proportions in the three stages are 31-0, 32*6 and 36*4 per
23
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cent respectively. Among 383 patients treated by radical mastectomy alone,
35-5 per cent were in Stage I and the best survival rate for all stages combined
was 50 9 ± 3-3 per cent for those treated during the first 6 months; among
175 who were treated by radical mastectomy combined with radiotherapy only
21*1 per cent were in Stage I and 43*4 per cent were in Stage III, and the best
survival rate for all stages combined was 58-8 ± 8-4 per cent for patients treated
one year or more subsequent to the first symptom, who numbered 34. The
difference of 7-9 ± 9 0 between these survival rates is not statistically significant.
When the sites were subdivided into those in which the highest survival rates
were among the patients who came under treatment in less than 3 months and
those in which the highest rates were among those treated in the second 3 months,
it was found that the former included squamous carcinoma of the skin, corpus
uteri, penis and female breast with a survival rate for all groups of 54-9 per cent,
while the latter included cervix uteri, kidney,.papillary carcinoma ofthe bladder
and carcinoma ofthepharynx (treated byradical surgery or by combinedmethods)
with a 5-year survival rate for all groups of 51X0 per cent.
The age distribution of 702 patients with cancer ofthe breast who were.treated
by radical mastectomy alone, of 393 who were treated by radical mastectomy
combined with radiotherapy, of 80 patients with cancer ofthe corpus uteri treated
by panhysterectomy and of 95 with cancer of the cervix uteri treated by Wer-
theim's hysterectomy were investigated by Harnett (1948, 1949); in addition
that of 138 patients with squamous carcinoma ofthe skin and of40 with carcinoma
or hypernephroma of the kidney have been tested by the x2 test,, but in no case
were there any significant differences between the observed and expected survivals
in the different age groups.
When the 616 patients who came for treatment within the first 6 months were
classified according to the stage of the disease at the time of commencing treat-
ment, it was found that 46*6 per cent were in Stage I, in which the disease is
still local, and 53-4 per cent were in later stages with involvement of regional
lymph nodes or invasion of adjacent tissues or both.
B. The highest percentage of 5-year survivals was among the patients who were
treatedfrom 6 to 12 months after thefirst symptom.
TABLE III.
0-6 months. 6-12 months. Over 12 months. Not known.
Site. , , ,
No. Survd. No. Survd. No. Survd. No. Survd.
Salivary glands . . . 5 4. 2 2 .19 13. 1
Tonsil . . .13 3. 1 1. 4 2 -
Testis . . . .19 10. 4 3. 8 6. 1 1
Colon, all sites . . 187 63 . 34 12 . 63 20 . 13 3
Skin, malignant melanoma . 14 3 . 9 3 . 12 2 . 2 -
Nasal sinuses . . . 25 5 . 8 2 . 3 -. 2 1
Bladder, infiltrating carcinoma 38 5 . 14 3 . 13 2 . 2
Stomach . . . .98 11 .62 15 .63 9. 18 2
Totals . . . 399 104 . 134 41 . 185 54 . 39 7
Per cent survived . . 26 1 30 6 29*2 18*0
_ ,
Difference . . .4- 5 1 4
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Detailed figures of survival by stages are given in Table IV for the colon
(all sites) and the stomach; for the other regions in the group all stages are com-
bined.
TABLE IV.
Colon (all 8ite8).
Stage I. Stage II. Stage III.
Duration. e- , f-
No. Survd. No. Survd. No. Survd.
0-6 months . 105 39 . 35 12 . 47 12
6-12 ,, . 15 6 . 12 4 . 7 2 .
Over 12 ,, . 31 10 . 19
Totals.
r Per cent.
No. Survd.
187 63 . 33-7±3*4
34 12 . 35-3±582 }.
5 . 13 5 . 63 20 . 31-7±5*9
Differ-
ence.
1*6
±8-9
3'6
}±101
Not known . 7 3 . 3 - . 3 - . 13
The differences in survival rate are not statistically significant.
For cases of known duration X2= *135, n=2, P < *95> *90.
Stomach (all site8). _ _ ___
3
Stage I. Stage II. Stage III. Totals.
Duration. , t -'t, Per cent.
No. Survd. No. Survd. No. Survd. No. Survd.
0-6 months . 38 7 . 50 2 . 10 2 . 98 11 . 11-2±3-2
6-12 ,, . 25 11 . 30 3 . 7 1 . 62 15 . 24-2±5-4}
Differ-
ence.
13*0
±693 9.9
Over2,, . 23 5 .35 4. 5 -. 63 9 .14*3±44 3±±4 Not known . 8 - . 6 2 . 4 - . 18 2
The difference between the survival rates ofthose operated on within 6 months and those operated
on in the second 6 months from the first symptom, 13±6- 3, is statistically significant.
For cases of known duration x2=4 95, n=2, P < * 10> *05.
Salivary glands.
Duration.
All stages.
No. Survd.
0-6 months . . . 5 4
6-12 ,, . . . 2 2
Over 12 ,, . . . 19 13J
Not known . . . 1 -
The difference is not statistically significant.
For cases of known duration x2= 158, n=1, P < *70> >50.
Ton8il.
Duration.
Per cent.
80*0+17'9
71-4+ 9.8
All stages.
, A. Per cent.
No. Survd.
0-6 months . . . 13 3
6-12 ,, . . . 1 1
Over 12 ,, . . . 4 2
The difference is not statistically significant.
For cases of known duration X2=2*23, n=1, P < *20> * 10.
23-1±11'7
60' 0±21. 9
Difference.
856±20'4
Difference.
36'9±24 8
Testis (excluding cases of teratoma).
Duration.
0-6 months .
6-12 ,,
Over 12 ,,
Not known
All stages.
No. Survd.
19 10
4 3
8 6
1 1
Per cent. Difference.
52 6±11.4}. 22-4±17'0
. 75-0±12-5
The difference is not statistically significant.
For cases of known duration x2=1 -56, n=1, P <' 30> *2(.26 W. L. HARNETT
TABLE IV-contin,ued.
Skin-malignant melanoma.
All stages.
Duration. A_ Per cent. Difference.
No. Survd.
0-6 months . . 14 3 .21-4+10-9 119±9 6-12 ~,9 3 33-3±15 7f 1197±19-0 Over 12 ,, . . 12 2 . 16-6±10.7}J 16 ±190
Not known . . . 2 -
The differences in survival rate are not statistically significant.
For cases of known duration x2 = *834, n=2, P < 70>
-50.
Bladder-infiltrating carcinoma.
All stages.
Duration. A Per cent. Difference.
No. Survd.
0-6 months . 38 5 .13.2± 5.5 85 212 6-12 ,, 14 3 214±10.9)} 8620±1242 Over 12 ,, . . . 13 2 . 15-4±10-0
Not known. . . . 2 -
The differences in survival rate are not statistically significant.
For cases of known duration x2= *54, n=2, P < *80> *70.
Na8al 8inuses.
All stages.
Duration. ,A Per cent. Difference.
No. Survd.
0-6 months 25 5 . 2010±860\ 8±14*1 6-12 ,, . 8 2~ 1821
Over12 ,, . . 3 -
. 1-2 1-
Not known . . . 2 1
The differences in survival rate are not statistically significant.
For cases of known duration X2= *016, n=1, P < *90>
- 80.
There are no significant differences between the survival rates of the three
groups of patients with carcinoma of the colon, nor were any found when the
figures for the different regions of the colon were examined separately. In the
case of the stomach, however, the best results of operation were in the group of
62 patients treated in the second 6 months from first symptom, whose survival
rate was 24-2 per cent against 11P2 per cent for 98 operated on within the first
6 months; the difference of 13-0 + 6-3 is statistically significant. The group
of 63 in whom the symptoms were of over 12 months' standing at the time of
operation had a survival rate of 14 3 per cent; the difference of9 9 ± 7 0 between
this figure and that for the group treated in the second 6 months is not statistically
significant. Ifthe patients are grouped into those ofless than 6 months' duration,
with a survival rate of 11-2 per cent, and those of over 6 months' duration, with
a survival rate of 19-2 per cent, the difference of 8-0 ± 4-7 is not significant.
The age distribution of the patients with cancer of the stomach and colon
were investigated by the x2 test, but in neither case were there any significant
differences between the observed and expected survivals in the different age
groups; for the stomach cases P < *20 > *10 and for the colon cases P < -70
> .50, showing that the differences in survival rates were not due to differences
in age distribution. The survival rate for cancer of the stomach was 20-4 per
cent for 108 patients in the age groups 25-54 and 11.1 per cent for 133 patients
of 55 and upwards, but the difference of 9.3 ± 4-7 is not significant, though the
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treated in the second 6 months were distributed evenly over the age-groups,
with the greatest number in the 45-54 group.
When the 134 patients who came under treatment 6-12 months from the first
symptom and had the best survival rate were classified according to the stage
which the disease had reached when treatment was commenced, it was found that
39*6 per cent were still in Stage I and 60*4 per cent were in later stages.
C. The highest percentage of 5-year survivals was among the patients who were
treated 12 months or more subsequent to the first symptom.
Site.
Intrinsic larynx
Thyroid gland.
Vulva and female urethra
Lip, upper and lower
Bone sarcoma (all types)
Ovary, malignant papillary cystE
Sarcoma of soft tissue
Rectum, ampulla
Eye
Male breast
Recto-sigmoid .
Tongue
Anal canal and anus
Ovary, carcinoma
Mouth, all sites
Prostate.
Totals
Per cent survived
Difference
TABLE V.
0-6 months. 6-12 months. Over 12 mont
No. Survd. No. Survd. No. Surv
8 3. 6 2. 9 7
23 12 . 6 4 . 20 14
22 8 . 14 6 . 16 11
27 10 . 10 5 . 18 12
.27 10. 7 4. 8 5
44 16 . 11 6 . 12 7
35 17 . 4 2 . 30 17
.137 42. 70 22. 61 31
32 12 . 8 4 . 10 5
3 - . 2 1. 4 2
56 15 . 39 9 . 25 11
47 15 . 9 3 . 14 6
.16 5. 8 1. 8 3
.37 6. 6 -. 8 3
51 8 . 7 1 . 13 4
19 3 . 8 2 . 10 3
.584 182 .215 72 .266 141
31-2 33.5 53 0
ths.
rd.
2 3 19
For the whole group of 1065 cases of known duration the survival rate of 799
patients who were treated within 12 months of the first symptom was 31-8 per
cent, whereas for 266 who were treated later it was 53-0 per cent. Detailed
figures of survival by stages are given below for the vulva, lip, ovary (malignant
papillary cysts), ampulla of rectum, recto-sigmoid, tongue and mouth. For
other regions all stages are combined.
TABLE VI.
Vulva andfemale urethra.
Stage I. Stage II. Stage III. Totals.
Duration. A
No. Survd. No. Survd. No. Survd. No. Survd.
0-6 months . 14
6-12 ,, . 10
Over12 ,,
Not known
Per cent. Differ-
ence.
8 . 1 - . 7 - . 22 8 . 36-4±10-2 6-5
5 * - . 4 1 . 14 6 . 42L9±13-2 25±68
8 . 1 1 . 4 2 . 16 11 . 68 7±11-6 f±17-6
- . 3 - . 3 -
The differences in survival rate are not statistically significant.
For cases of known duration x2=4. 11, n=2, P < *20> * 10.
Not known.
No. Survd.
3 3
3 -
2 1
1 -
2 1
3 1
11 -
7 3
7 3
3 -
3 1
1 -
46 13
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TABLE VI-continued.
Lip, upper and lower.
Stage
Duration.
No. Su
0-6 months . 16
6-12 ,, . 4
Over 12 ,, . 14 ]
Not known . 2
I. Stage II. Stage III. Totals. Differ.
irvd. No. Survd. No. Survd. No. Survd. ence.
8 . 1 - . 10 2 . 27 10 . 370± 9 3 13-0
2 . - - . 6 3 . 10 5 . 50*0±15S-8 +1686
Ll . 1 - . 3 1 . 18 12 . 66-6+11-1 j±19-3
1 . - . - - . 2 1
The differences in survival rate are not statistically significant.
For cases of known duration X2=3 * 794, n=2, P < *20>
- 10.
Ovary-malignant papillary cy8t8.
Stage I. Stage II. Stage III. Totals.
Duration., , ^
No. Survd. No. Survd. No. Survd. No. Survd.
0-6 months . 36 15. 8 1. - - .44 16.
6-12 ,, . 9 5. 2 1 .- -. 11 6.
Over 12 ,, . 10
Not known . 2
7 . 2
1. -
- . - 7- . 12 7.
- . - . 2 1
Differ- Per cent. ence.
36-4+ 7*2 18.1
54-5±15-0 ± 16-7 35 8
58*3±14-2 .f±20-7
The differences in survival rate are not statistically significant.
For cases of known duration x2=2*56, n=2, P < *30> -20.
Rectu4m, arnpull~a.
Stage I. Stage II. Stage III. Totals.
Duration. , ,1-,
No. Survd. No. Survd. No. Survd. No. Survd.
0-6 months . 40 19 . 44 14 . 53 9 . 137 42 .
6-12 ,, . 22 9 .25 8 .23 5 .70 22.
Over 12 ,, . 16 11 . 23 11 . 22 9 . 61 31 .
Per cent. Differ.
ence.
30 7±3 9 0-7
31-4±5 6 l 6 89 19 4
50*8±6-4 {85
Not known . 6 - . 3 - . 2 - . 11 -
The difference of 19-4±8-5 per cent between the survival rate of those patients who were
treated in the second 6 months and of those whose duration was more than 12 months is statistically
significant.
For cases ofknown duration X2=8 * 17, n=2, P < *02> *01.
. 15
. 13
. 9
Not known . 3
Stage I. Stage II. Stage III. Totals.
No. Survd. No. Survd. No. Survd. No. Survd.
Per cent. Differ-
ence.,
3 . 17 6 . 24 6 . 56 15 . 26-8+5*9i 3.7
4 . 10 4 . 16 1 . 39 9 . 23-1+6o7
±9 20*9
6 . 8 4 . 8 1 . 25 11 . 44.0±9.9 f±12-0
2 . 4 1 . - - . 7 3
The differences in survival rate are not statistically significant.
For cases of known duration X2=3*52, n=2, P < * 20> * 10.
Recto-8igmoid.
Duration.
0-6 months
6-12 ,,
Over 12 ,,
628DELAY IN TREATMENT OF CANCER AND SURVIVAL RATE
TABLE VI-continued.
Tongue.
Stage I. Stage II. Stage III. Totals.
Duration. , A- , ,
-
No. Survd. No. Survd. No. Survd. No. Survd.
0-6 months . 29 12 . 2 1 . 16 2 . 47 15.
6-12 ,, . 7 3 . - - . 2 - . 9 3.
Over 12 ,, . 9 5 . - 5 1 . 14 6 .
Per cent. Differ-
ence.
31*9±6*S } 1-4
33-3±15.7 917'6
42*9±13*2 ±t20.5
The differences in survival rate are not statistically significant.
For cases of known duration x2=-585, n=2, P <*80>
-70.
Mouth-all 8ite8.
Stage I. Stage II. Stage III. Totals.
Duration , A -- t -5
No. Survd. No. Survd. No. Survd. No. Survd.
0-6 months . 21 5 . 10 1 . 20 2 . 51 8 .
6-12 ,, . 3 1 . - - . 4 - . 7 1 .
Over 12 ,, . 9
Per cent. Differ-
ence.
15-7± 5*1) 1.4
14*3±13 2f ±14Q2 9' OA
5 . - - . 5 1 - 14 6 . 42-9±13.2 ±18-7
The differences in survival rate are not statistically significant.
For cases of known duration x2=1 65, n=2, P < *50> *30.
Intrinsic larynx.
Duration.
0-6 months .
6-12 ,,
Over 12 ,
All stages.
No. Survd.
8 3
6 2
9 7
Per cent. Difference.
. 3735-17}4 42251 7 33.3±19.2) 44-4±23*7 77-7±13*9}4 427
The differences in survival rate are not statistically significant.
For cases of known duration x2=3 92, n=2, P <
-20> 10.
Thyroid Gland,
Duration.
0-6 months .
6-12 ,
Over 12 ,,
Not known
All stages.
No. Survd.
23 12
6 4
20 14
3 3
Per cent. Difference.
6 522+210}4 143 421 9
70660±19-2 }3-4±21-8
The differences in survival rate are not statistically significant.
For cases of known duration x2=1 55, n=2, P < 50> .30. If the 3 cases of unknown duration
are included x2=3 505, n-3, P <*50>
-30.
Bone sarcoma (all types).
Duration.
0-6 months
6-12 ,,
Over 12 ,
Not known
All stages.
.
No. Survd.
27
7
8
1
10
4
5
Per cent. Difference.
37 0± 937 20-1±20-9 571+18-75j ±2- 62-5±17-1 )542-
The differences in survival rate are not statistically significant.
For cases of known duration x2=2-09, n=2, P < *50> -30.
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TABLE VI-continued.
Soft tissue sarcoma (all types).
Duration.
0-6 months .
6-12 ,,
Over 12 ,
Not known
All stages.
No. Survd.
35 17
4 2
30 17
3 1
Per cent. Difference.
48 7±8-0-L
56 6±9-Of
- 79±12 1
The difference in survival rate is not statistically significant.
For cases of known duration X2= *44, n=1, P < * 70> *50.
Eye (all types of malignant grot
Duration.
0-6 months .
6-12 ,,
Over 12 ,,
Not known
All stages.
No. Survd.
32 12
8 4
10 5
7 3
The difference in survival rate is not statistically significant.
For cases of known duration x2=*73, n=2, P < *70> *50.
Anal canal and anus.
Duration.
0-6 months .
6-12 ,
Over 12 ,
Not known
All stages.
No. Survd.
16 5
8 1
8 3
2 -
Per cent. Difference.
3152±1-6 } }1827+16.4
12-5±1171 }25.0±20.7
The differences in survival rate are not statistically significant.
For cases of known dutfation X2_1 -39, n=2, P< <50> 30.
Ovary-carcinoma and sarcoma.
Duration.
0-6 months .
6-12 ,,
Over 12 ,,
Not known
All stages.
No. Survd.
37 6
6 -
8 3
3 1
Per cent. Difference.
. 16*2± 6 0)
0*0
. 37*5±17 1J
21*3±18 1
The difference in survival rate is not statistically significant.
For cases of known duration X2=3X51, n=2, P < -20> .10.
Prostate.
Duration.
0-6 months .
6-12 VP
Over 12 ,
Not known
All stages.
No. Survd.
19 3
8 2
10 3
1 -
The differences in survival rate are not statistically significant.
For cases of known duration X2 = * 85, n=2, P <* 70> *50.
In all these sites the 5-year survival rates of those patients who came under
treatment 12 months or more after the first symptom were better than those
ofthe patients who were treated at an earlier stage, but the only difference which
is statistically significant is between the survival rate of 50.8 per cent for 61
Per cent. Difference.
37-5± 8-5 125±9 50 0±17 7}} 1205+19. 6
. 50.0±15g8
Per cent. Difference.
* 158+± 8*4 942±1o 25*0+15 3J 9.02±170 30*0±14*5}5±20
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patients with cancer of the ampulla of the rectum of over 12 months' standing
and 31-4 per cent for 70 patients whose disease was of 6-12 months' standing,
difference 19-4 ± 8-3. When the survival rates for cancer of the ampulla of the
rectum were tested by the x2 test the value of P < *02 > *01 was found, mainly
due to the difference between the observed and expected survivals in the group
of over 12 months' duration.
The age distribution of the patients with cancer of the recto-sigmoid and of
those with cancer of the ampulla of the rectum were investigated by the x2 test,
but in neither case were any significant differences found between the observed
and expected survivals; for both regions P < 90 > *80, showing that the
differences in survival rates were not due to differences in age distribution.
When the 266 patients who came under treatment more than 12 months
from the first symptom and had the highest survival rate were classified according
to the stage ofthe disease at the time ofcommencing treatment, it was found that
53-8 per cent were still in Stage I and 46-2 were in later stages, a higher percentage
of Stage I cases than in either Group A or Group B.
In Table VII all three groups are combined:
TABLE VII.
0-6 months. 6-12 months. Over 12 months. Not known.
(or)lip. Duration.
No. Survd. No. Survd. No. Survd. No. Survd.
A .0-6 months. .616 315 .211 83 .270 119 .48 15
B .6-12,, . .399 104 .134 41 .185 54 .39 7
( .Over12,, . .584 182 .215 72 .266 141 . 46 13
Totals . .1599 601 . 560 196 . 721 314 . 133 35
Per cent survived . 37-6 35 0 43-6 26 3
Difference . 2-6 8 6
TABLE VIII.-Grand Totals of Cases of Known Duration.
Duration. No. Survived. Per cent. Difference.
Under 12 months 2159 . 797 . 36.9 6-7
Over ,, . 721 . 314 . 43 6 J
The difference ofsurvival rate between thosewho weretreatedwithin 6 months
ofthe first symptom and those who were treated 6-12 months from the first symp-
tom is small, but the survival rate of those who were treated after a delay of 12
months or more is greater than that of the other two groups, either combined
or separately; numerically the latter group comprises about one-quarter of all
cases. As has been stated above this difference cannot be accounted for by
differences in the age distribution of patients in either of the groups, so it must
be presumed to be due to variations in the rate of growth of individual tumours
and in their infiltrating and metastatising powers. All cases of patients with
distant metastases have been eliminated from the present series, which was
confined to those in which the tumour was local or had given rise to clinically
recognisable metastases in lymph nodes; they were selected as operable cases,
no patient in an advanced stage or suitable only for palliative treatment being
included. Small differences were found in the proportion of patients in Stage I
among those with the highest survival rate in each ofthe three groups; for Group
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A this was 46*6 per cent, for Group B it was 39-6 per cent and for Group C it was
53-8 per cent, but the combined figures for all the patients in each group showed
only small deviations from the mean.
Classification by Stages ofall Cases ofKnown Duration.
TABLE IX.
A.
Stage. 0-6 months.
No. Per cent.
I . 526 47 9
II . 315 28 7
III . 256 23 3
Totals . 1097 99 9
B.
6-12 months.
No. Per cent.
323 45 0
256 35-7
139 19-4
718 100 1
C.
Over 12 months.
I t
No. Per cent.
550 51*6
234 22-0
281 26 4
1065 100*0
Totals.
No. Per cent.
1399 48-6
805 28 0
676 23-5
2880 100.1
The highest percentage of Stage I cases is among the patients whose disease was
of over 12 months' standing (Group C), probably due, like the difference in sur-
vival rates between those treated early and those treated later, to variations in
the intrinsic growth-rate of the tumours themselves. Park and Lees (1951)
point out that this may be estimated by (a) the histological appearance of the
tumour, disregarding size or degree of extension at the time of diagnosis, or (b)
by duration of survival from the onset of symptoms or time of treatinent to
death in untreated or unsuccessfully treated cases, though in the latter case
the survival time may be affected by the treatment.
Pathology.
Histological reports were available in 88 per cent of the 3013 cases. In 376
cases the histological grade of the growths according to Broders' classification
was given, but as these reports were the work of several different pathologists
the system of grading used may not have been uniform; moreover the cases
in which these particulars were given were so few that there were rarely enough
in any one site to provide material for an analysis. For all sites combined there
were 134 survivors of the 376 patients (35.6 per cent) graded as shown in Table
X.
TABLE X.
Grade.
I
II
III
IV
No.
83
153
66
74
Survived.
40
57
17
20
Per cent.
48-2
37.3
25 8
27-0
Table XI shows the 376 cases arranged according to grade and duration of
symptoms prior to treatment.
TABLE XI.
Grade.
I
II
III
IV
Totals
Percentage in
Grades I and II
0-6 months.
36
74
40
39
189
58 2
6-12 months.
21
39
8
22
90
Over 12months.
23
34
15
10
82
66 6 . 69 5
Not known.
3
6
3
3
15
Totals.
83
153
66
74
376
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TABLE XI-continued
Rectum and recto-8igmoid-l 17 cases.
Grade. 0-6 months. 6-12 months. Over 12 months. Not known. Totals.
I . 2 . 4 . 2 . 1 . 9
II . 34 . 23 . 19 . 1 . 77
III . 15 . 4 . 3 . 3 . 25
IV . 2 . 3 . 1 . - 6
Totals . 53 . 34 . 25 . 5 . 117
Percentage in
Grades I and II 680 . 79 4 . 840 . 40'0 . 73.5
The differences are not significant. x2=2 84, n=2, P < *30> *20.
Stomach-35 cases.
Grade. 0-6 months. 6-12 months. Over 12 months. Not known. Totals.
I . 4 . 3 . 3 . 1 . 11
II . 1 . 2 . 1 . 1 . 5
III . 2 . . 2 . - . 4
IV . 9 . 2 . 4 . - . 15
Totals . 16 . 7 . 10 . 2 . 35
Percentage in
GradesI and II. 31-2 . 71-4 . 40 0 . 100.0 . 45.7
The differences are not significant, but it has been shown in an earlier section that the highest
survival rate among patients with cancer of the stomach was among those in whom the delay in
treatment was 6-12 months. x2=3 47,n=2,P< 20>*10.
Scanty as these data are, they are in accord with Bloom's (1950b) findings
that a higher percentage ofpatients with tumours ofGrades III and IV come early
for treatment than of those with the lower grades.
Duration ofsurvival of untreated patients.
Many patients were not treated for various reasons, and the total duration
of the disease from first sympton to death is known in most of these. Patients
who were in Stage IV of the disease with distant metastases have not been in-
cluded in the following list, in which the sites are arranged in order of mean dura-
tion of survival of patients in Stages I, II and III in whose cases treatment was
withheld for other reasons than the advanced stage of the disease (Table XII).
The actual duration of survival expressed in months is given, and also expressed
as a percentage of the normal expectation of life during the next 5 years for a
group of persons having the same sex-age distribution as the group of cancer
patients under consideration (Table XII).
The last column of Table XII refers to the three groups into which the sites
were divided according to the survival rates in relation to delay in commencing
treatment; the figures show that there is no correspondence between these
groups and the duration of life in the untreated cases. The mean duration of
life in 153 untreated patients in Group A was 23-1 months, of 176 in Group B was
11-7 months and of 296 in Group C was 17-6 months. The sites showing the
longest survivals among the untreated patients are those in which treatment
by radical surgery alone or with radiotherapy gives the best results, although
some sites show a short duration of life, either because, as in the case of the lip,
very few cases are left untreated, or because, as in the case of the colon and the
intrinsic larynx, untreated patients often die of complications, such as intestinal
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TABLE XII.
Number of Actual Percentage
Site. patients. duration of normal Group.
in months, expectation.
Breast . . . . 53 . 35 9 . 7278 . A
Skin, squamous carcinoma 7 . 34'9 . 74-6 . A
Recto-sigmoid. . . 29 . 224 . 43-9 . C
Bladder, papillary carcinoma 23 . 220 . 43.3 . A
Anus and anal canal . . 14 . 21*9 . 44.5 . C
Prostate. . . . 43 . 19 5 . 39 2 . C
Vulva . . . . 9 . 19 1 . 40-0 . C
Rectum, ampulla . . 132 . 190 . 38-5 . C
Cervix uteri . . . 26 . 17v 5 . 31v 6 . A
Corpus uteri . . . 7 . 17-4 . 32-9 . A
Thyroidgland . . . 8 . 15-6 . 29-1 . C
Bladder, infiltrating car-
cinoma . . . 80 . 14-0 . 27-0 . B
Nasalsinuses . . . 11 . 13-0 . 25-2 . B
Mouth, floor of . . . 11 . 12-6 . 24-7 . C
Stomach,pylorus . . 27 . 11-5 . 22-1 B
Mouth, alveolus . . 5 . 10-S8 . 22-2 . C
,, palate. . . 8 . 100 . 20-9 . C
Lip,upper(1),lower(2) . 3 . 10-0 . 22- C
Ovary, carcinoma . . 5 . 9-6 . 18-0 . C
Tongue . . . . 14 9-1 . 17-2 . C
Intrinsic larynx . . 15 . 9-0 . 17-9 . C
Tonsil . . . 7 . 8-7 . 18-5 . B
Colon (all sites). . . 31 . 8-7 . 17-4 . B
Stomach, mid-gastric. . 12 . 8-7 . 17-6 . B
Pharynx. . . . 28 . 8-4 16-3 . A
Kidney . . . . 9 . 7.7 13-8 A
Stomach, cardiac . 8 . 5-7 11-3 . B
obstruction or broncho-pneumonia comparatively early in the growth of the
tumour. In some sites, for example salivary glands, malignant melanoma of
skin, penis, testis, sarcoma of soft tissue and of bone, all patients were treated
except those whose disease was in Stage IV. The remaining sites in which the
duration of survival of untreated patients was less than 12 months-mouth,
ovary (carcinoma), tongue, tonsil, stomach and pharynx-are sites in which the
results ofradicalsurgery are not sogood as in those in which the natural duration
of the disease is longer. The conclusion to be drawn is that the growth rate of
the tumour is the most importantfaotor influencing the survival rate after radical
surgical treatment, leading torelativelylong survival in spite ofdelay incommenc-
ing treatment.
SUMMARY.
1. The 5-year survival rates of 2880 patients, whose disease was in Stages
1, II and III and who were treated by radical surgery alone or with radiotherapy,
were analyzed to ascertain whether the interval between first symptom and
commencement oftreatment was directly related to the survival rate.
2. Itwas found that the sites ofthe disease could be divided into threegroups:
A. Those in which the highest percentage of 5-year survivals was among the
patients treated within the first 6 months from firstsymptom. B. Those in which
it was among the patients treated 6-12 months from first symptom. c. Those
in which it was among the patientstreated 12 months or more subsequent to the
first symptom.
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3. Group A included the skin (squamous carcinoma), corpus uteri, penis,
cervix uteri, female breast, kidney, bladder (papillary carcinoma) and pharynx.
For this group ofsites, comprising 1097 cases ofknown duration, the best survival
rate was 51 1 per cent of 616 patients treated in the first 6 months against 42-0
per cent for the remainder. The differences in survival rate were calculated for
individual sites, but only those for the skin and one of the differences for the
kidney were found to be statistically significant.
4. Group B included salivary glands, tonsil, testis, colon, skin (malignant
melanoma), nasal sinuses, bladder (infiltrating carcinoma) and stomach. For
this group of sites, comprising 718 cases of known duration, the best survival
rate was 30-6 per cent of 134 patients treated in the second 6 months against
27 1 per cent for the remainder. None of the differences in survival rate for
individual sites was significant, except that for caroinoma of stomach (all sites)
of duration 0-6 months and that for duration 6-12 months, which was 13-0
± 6-3 per cent. For all 223 cases of carcinoma of stomach of known duration
the survival rates of the cases of 0-6, 6-12 and over 12 months' interval groups
tested by the x2 test gives the value of P < *10 > -05 for the difference between
observed and expected survivals, which is not statistically significant.
5. Group c included intrinsic larynx, thyroid gland, vulva, lip, bone sarcoma
and soft tissue sarcoma, ovary, rectum (ampulla), recto-sigmoid, eye, male
breast, anal canal and anus, tongue, mouth and prostate. For this group of
1065 cases of known duration the best survival rate was 53 0 per cent of 266
patients treated more than 12 months from the first symptom against 31-8 per
cent of 799 patients treated earlier. In individual sites the only difference which
was statistically significant was that between the survival rate of cases of car-
cinoma of the ampulla of the rectum treated within 12 months of onset, 31-4
per cent and those treated later, 50-8 per cent, difference 19-4 ± 8-5.
6. The age distribution ofthepatients was investigated for the most important
sites, but in none was any significant difference found between observed and
expected survivals due to the differences in age distribution.
7. The highest percentage of patients whose disease was still in Stage I-
51-6 per cent-was in Group c, in which the best survival rate was among the
patients treated more than 12 months subsequent to the first symptom. It
was concluded that thedifferences in survival rate were probably due to variations
in the intrinsic growth rate of the tumours.
8. Only comparatively few observations on the grading ofthe tumours accord-
ing to Broders' system were available, but those for carcinoma of the stomach
and rectum supported the view that patients with slow-growing tumours formed
a high percentage of those who delayed longest before coming for treatment.
9. The total duration of the disease was calculated for 625 patients in Stages
I, II and III who were not treated. It was found that the sites showing the
longest survivals of untreated patients were those in which the results of radical
surgery were most satisfactory.
My thanks are due to the British Empire Cancer Campaign for permission
to make use of the records of cases of cancer in London hospitals collected by
the Clinical Cancer Research Committee ofthe Campaign, and to Dr. Percy Stocks
for his invaluable advice and help in the statistical treatment of the data.
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